Aspirin intake and head and neck cancer: A pooled analysis within the INHANCE consortium

Head Neck. 2024 Apr;46(4):926-935. doi: 10.1002/hed.27638. Epub 2024 Jan 16.


Background: Aspirin intake might be inversely associated with head and neck cancer (HNC). Thus, we investigated this relationship within the International Head and Neck Cancer Epidemiology (INHANCE) consortium.

Methods: Four case-control studies within the INHANCE consortium were included (2024 cases, 4196 controls). Study-specific odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using logistic regression and subsequently pooled with DerSimonian-Laird random-effects model. Nonlinearity of the relationship between duration of intake and HNC was modeled with fractional polynomials.

Results: Aspirin was inversely associated with HNC overall (OR = 0.48; 95% CI: 0.26, 0.91). Results for laryngeal cancer were similar (OR = 0.54; 95% CI: 0.30, 0.96). Analysis on duration of intake confirmed findings for HNC overall, showing also inverse associations for oropharyngeal and laryngeal cancer.

Conclusions: This study suggests that aspirin intake may reduce the risk of HNC, driven mainly by decreases in risk for laryngeal and oropharyngeal cancer.

Keywords: aspirin; case-control; consortia; head and neck cancer.

Publication types

  • Meta-Analysis

MeSH terms

  • Case-Control Studies
  • Head and Neck Neoplasms* / epidemiology
  • Head and Neck Neoplasms* / prevention & control
  • Humans
  • Laryngeal Neoplasms* / epidemiology
  • Oropharyngeal Neoplasms*
  • Risk Factors